Effects of rehabilitative exercise on peripheral muscle TNFα, IL-6, IGF-I and MyoD expression in patients with COPD

Ioannis Vogiatzis, Grigoris Stratakos, Davina C M Simoes, Gerasimos Terzis, Olga Georgiadou, Charis Roussos, Spyros Zakynthinos

Background: Skeletal muscle wasting commonly occurs in patients with chronic obstructive pulmonary disease (COPD) and has been associated with the presence of systemic inflammation. This study investigated whether rehabilitative exercise training decreases the levels of systemic or local muscle inflammation or reverses the abnormalities associated with muscle deconditioning.

Methods: Fifteen patients with COPD (mean (SE) forced expiratory volume in 1 s 36 (4)% predicted) undertook high-intensity exercise training 3 days/week for 10 weeks. Before and after the training programme the concentration of tumour necrosis factor α (TNFα), interleukin-6 (IL-6) and C-reactive protein (CRP) in plasma was determined by ELISA, and vastus lateralis mRNA expression of TNFα, IL-6, total insulin-like growth factor-I (IGF-I) and its isoform mechanogrowth factor (MGF) and myogenic differentiation factor D (MyoD) were assessed by real-time PCR. Protein levels of TNFα, IGF-I and MyoD were measured by Western blotting.

Results: Rehabilitation improved peak exercise work rate by 10 (2%) (p = 0.004) and mean fibre cross-sectional area from 4061 (254) μm² to 4581 (241) μm² (p = 0.001). Plasma inflammatory mediators and vastus lateralis expression of TNFα and IL-6 were not significantly modified by training. In contrast, there was a significant increase in mRNA expression of IGF-I (by 67 (22)%; p = 0.044), MGF (by 67 (15)%; p = 0.002) and MyoD (by 116 (30)%; p = 0.001). The increase observed at the mRNA level was also seen at the protein level for IGF-I (by 72 (36)%; p = 0.046) and MyoD (by 67 (21)%; p = 0.012).

Conclusions: Pulmonary rehabilitation can induce peripheral muscle adaptations and modifications in factors regulating skeletal muscle hypertrophy and regeneration without decreasing the levels of systemic or local muscle inflammation.

Inflammatory activation with increased serum levels of mediators such as tumour necrosis factor α (TNFα), interleukin (IL)-6 and acute phase reactant proteins such as C-reactive protein (CRP) have been described as important factors in the progression of chronic obstructive pulmonary disease (COPD). Although the involvement of systemic cytokines (such as TNFα and IL-6) in peripheral muscle dysfunction has never been directly documented in COPD, the available literature strongly supports a casual relationship. Importantly, in two studies enhanced levels of TNFα have been found in the skeletal muscle of patients with COPD compared with age-matched healthy controls, whereas in another study local muscle TNFα could not be detected.

Recent experimental data suggest that TNFα interferes with the action of muscle insulin-like growth factor-I (IGF-I), thereby leading to muscle atrophy. In addition, TNFα inhibits myogenic differentiation through destabilising myogenic differentiation factor D (MyoD) protein, thus interfering with skeletal muscle regeneration. Furthermore, in a rodent local infusion model, IL-6 resulted in muscle atrophy characterised by preferential loss of myofibrillar protein.

Skeletal muscle dysfunction is common in patients with advanced COPD and it contributes importantly to limiting their functional capacity and quality of life. Morphological and biochemical changes within the vastus lateralis muscle of these patients include abnormal fibre-type distribution, reduced fibre cross-sectional areas and decreased muscle capillarity and oxidative enzyme activities. We recently reported that both constant-load and interval training modalities improve exercise capacity by reversing, at least in part, the aforementioned muscle abnormalities. It remains, however, unknown whether exercise training simply reverses the abnormalities associated with muscle deconditioning or actually interferes with certain inflammatory factors, such as TNFα and IL-6, that have been proposed to be involved in the pathogenesis of COPD-related muscle dysfunction.

Rabinovich and colleagues were the first to report that exercise training does not decrease the levels of systemic or local muscle TNFα in patients with COPD; this report, however, did not provide direct evidence as to whether training actually slowed or even reversed the peripheral muscle abnormalities. On the other hand, although there are studies reporting no effect of exercise training on systemic levels of IL-6, the impact of pulmonary rehabilitation on the expression of local muscle IL-6 is unknown.

Interestingly, exercise training in healthy elderly individuals and in patients with chronic heart failure has been shown to be associated with upregulation of mRNA expression of total IGF-I, its load-sensitive splice variant termed mechanogrowth factor (MGF) and MyoD, all of which are important factors for skeletal muscle hypertrophy and regeneration. The possibility that this mechanism could also be an underlying cause of muscle adaptation in patients with COPD has not been investigated.

This study was therefore undertaken to investigate the effect of training on the local muscle expression of IGF-I, MGF and MyoD.

Abbreviations: COPD, chronic obstructive pulmonary disease; CRP, C-reactive protein; FEV₁, forced expiratory volume in 1 s; FVC, forced vital capacity; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; IGF-I, insulin-like growth factor-I; IL, interleukin; MGF, mechanogrowth factor; MyoD, myogenic differentiation factor D; TNFα, tumour necrosis factor α.
MyoD. The effect of training on systemic (plasma TNFα, IL-6 and CRP) and local muscle inflammation (expression of TNFα and IL-6) was also investigated. It was hypothesised that the training-induced skeletal muscle adaptations are accompanied by increased local muscle IGF-I, MGF and MyoD expression, but not with reductions of systemic or local muscle inflammation. The latter was based on the results of previous studies in COPD showing a lack of change in systemic and/or local muscle inflammation with exercise training.21

METHODS

Study population

Fifteen patients (three women) with clinically stable COPD met the following criteria: (1) post-bronchodilator forced expiratory volume in 1 s (FEV1) <50% predicted and FEV1/forced vital capacity (FVC) <70% without significant post-bronchodilator reversibility (<10% FEV1 % predicted normal); (2) optimal medical treatment according to GOLD28 without regular use of systemic corticosteroids; and (3) absence of other significant diseases that could contribute to exercise limitation. Four of these patients had also participated in a previous report.13 Ten age-matched subjects with FEV1 >92% predicted were also included in the present study. Patients and healthy subjects gave written informed consent that was approved by the university ethics committee.

Study design

Similar to our previous study,13 patients were admitted to an ongoing randomised controlled pulmonary rehabilitation trial consisting of two types of intensive exercise training (interval and constant-load) lasting 10 consecutive weeks. Since our previous work established no differences between training modalities in terms of muscle morphological characteristics,13 the present study aimed to determine the effect of exercise training per se on local muscle inflammatory and myogenic factors. Prior to and on completion of the programme, patients were assessed for pulmonary function, exercise tolerance and plasma inflammatory mediator levels. A muscle percutaneous biopsy was also performed.

Assessments

Assessments included: (1) resting pulmonary function, carbon monoxide transfer factor (TLCO) and subdivisions of lung volumes by body plethysmography (Medgraphics Autolink 1085D, Minnesota, USA); (2) arterial blood analysis (ABL330; Sensor Medics, California, USA) to the limit of tolerance 1085D, Minnesota, USA); (2) arterial blood analysis (ABL330; Sensor Medics, California, USA) to the limit of tolerance; and (3) absence of other significant factors. Prior to and on completion of the programme, patients were assessed for pulmonary function, exercise tolerance and plasma inflammatory mediator levels. A muscle percutaneous biopsy was also performed.

Exercise training programme

Patients performed high-intensity exercise either at a constant load (initially set at 60% Wpeak for 30 min; n = 8) or at intervals of 30 s work alternating with 30 s rest (load initially set at 100% Wpeak, for 45 min, n = 7). Exercise was performed on electromagnetically braked ergometers (CatEye-Ergociser, EC-1600; Osaka, Japan) as previously described.13 22 25 The workload was increased on a weekly basis as detailed below. As in our previous rehabilitation studies,13 21 the exercise prescription was designed to present patients with a similar overall training load.

Plasma inflammatory mediators

Plasma was collected using EDTA 24 h before and 24 h after the rehabilitation programme. The concentration of mediators was determined by ELISA according to the manufacturer’s instructions (TNFα, IL-6 and CRP; R&D Systems, Minneapolis, Minnesota, USA). Samples of healthy controls were assayed together with the patient samples. The sensitivity of the respective assays was 0.12 pg/ml for TNFα, 0.04 pg/ml for IL-6 and 0.01 ng/ml for CRP.

Muscle biopsy

Previous work28 has shown that the mRNA content of both IGF-I and MyoD 24 h after an exercise bout does not differ from that before the exercise bout. Muscle percutaneous biopsy specimens of the right vastus lateralis muscle performed at mid-thigh (15 cm above the patella) were therefore obtained 24 h before the first and 24 h after the last training session and analysed blindly as previously described29 for fibre type classification and cross-sectional areas. In brief, muscle samples were cut into two pieces. One was placed immediately into liquid nitrogen and the other was aligned under a stereoscope in order to have most of the fibres in parallel. It was then placed in embedding compound and frozen in isopentane precooled to its freezing point. All biopsy specimens were kept at −80°C until the day of analysis. Cryostat transverse sections 10 μm thick from the embedded samples were cut at −20°C and stained for myofibrillar ATPase pre-incubation at pH 4.3, 4.6 and 10.3.27 A mean (SE) of 413 (39) muscle fibres were classified as type I, IIa or IIb from each sample. The cross-sectional area of at least 300 fibres from each sample was measured with an image analysis system (ImagePro; Media Cybernetics Inc, Silver Spring, Maryland, USA) at a known and calibrated magnification. The mean cross-sectional area of all fibre types was calculated, taking into account the relative contribution of each fibre type to the total surface.

Quantitative real-time PCR

Total RNA was extracted from 30 mg muscle biopsy specimens using an RNeasy Fibrous Tissue (Qiagen, West Sussex, UK). The total RNA was then quantified (260 nm) and adjusted to a concentration of 1 μg/μl. The cDNA was synthesised using 1 μl total RNA from each sample using a SuperScript First-Strand Synthesis System (Invitrogen, Carlsbad, California, USA) for real-time PCR according to the manufacturer’s instructions. 2 μl of each cDNA sample were used as a template for the amplification reaction using SyBR greenER qPCR Supermix Universal. Primer sequences for TNFα, IL-6, IGF-I total (IGF-Ieabc), MGF (IGF-Iec) and MyoD are given in table 1 (in the online supplement available at http://thorax.bmj.com/ supplemental). PCR amplifications were performed in triplicate in a Chromo4 Detector and PTC-200 Peltier Thermal Cycler and analysed with Opticon software 2.03 (MJ Research, Massachusetts, USA). The threshold cycle (Ct value) was chosen as the first amplification cycle giving a signal above background. To calculate the relative quantity of the respective genes, the ΔΔCt method was used.36 Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA expression was used for normalisation.37 More information on real-time PCR procedures is given in the online supplement (http://thorax.bmj.com/ supplemental).

Muscle protein immunoblotting

Vastus lateralis muscle biopsies stored at −80°C were homogenised in 10 volumes (wt/vol) of a lysis buffer as previously
Statistical analysis

The minimum sample size was calculated based on 80% power and a two-sided 0.05 significance level using the Statistica 7.0 statistical program. Sample size capable of detecting a change described.26 The protein concentration was determined using a DC protein assay (BioRad, Hercules, California, USA). Samples were subjected to SDS polyacrylamide gel electrophoresis (SDS-PAGE) followed by transfer to a polyvinylidene fluoride membrane (PVDF) (Millipore Corp, Bedford, Massachusetts, USA). Immunoblotting was carried out using primary antibodies raised against MyoD (1:200, Santa Cruz Biotechnology, USA) and TNF-α (1:1000, Santa Cruz Biotechnology). Blots were stripped and re-probed with a monoclonal anti-sarcomeric α-actinin antibody (1:1000, Sigma-Aldrich, St Louis, Missouri, USA). All bands were visualised using Chemiluminescent Substrate (Pierce, Rockford, Illinois, USA). Data were digitalised and quantified by densitometric analysis. More information on protein immunoblotting is given in the online supplement available at http://thorax.bmj.com/supplemental.

Table 1 Demographic and lung function characteristics of patients with COPD (n = 15) and age-matched healthy subjects (n = 10)

<table>
<thead>
<tr>
<th></th>
<th>COPD</th>
<th>Controls</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age (years)</strong></td>
<td>66 (7)</td>
<td>61 (5)</td>
</tr>
<tr>
<td><strong>BMI (kg/m²)</strong></td>
<td>25.9 (2.7)</td>
<td>28.8 (2.6)</td>
</tr>
<tr>
<td><strong>FEV₁ (%) [pred]</strong></td>
<td>0.94 (0.44) [35.7 (16.4)]</td>
<td>2.86 (0.8) [94.7 (5.4)]*</td>
</tr>
<tr>
<td><strong>FVC (%)</strong></td>
<td>47.0 (8.52) [71.3 (20.0)]</td>
<td>3.76 (0.9) [101.3 (11)]*</td>
</tr>
<tr>
<td><strong>FEV₁/FVC (%)</strong></td>
<td>36 (11)</td>
<td>77 (4)*</td>
</tr>
<tr>
<td><strong>TICO (%) [pred]</strong></td>
<td>40.2 (1.68)</td>
<td>81.2 (5.9)*</td>
</tr>
<tr>
<td><strong>TLC (%) [pred]</strong></td>
<td>7.92 (1.24) [126 (9)]</td>
<td>6.16 (0.21) [92 (5)]*</td>
</tr>
<tr>
<td><strong>IC (%) [pred]</strong></td>
<td>5.83 (0.76) [172 (14)]</td>
<td>3.22 (0.11) [96 (4)]*</td>
</tr>
<tr>
<td><strong>IC (%) [pred]</strong></td>
<td>4.52 (0.82) [209 (30)]</td>
<td>3.92 (0.09) [88 (7)]*</td>
</tr>
<tr>
<td><strong>IC (%) [pred]</strong></td>
<td>2.09 (0.60) [72 (10)]</td>
<td>2.96 (0.18) [92 (5)]*</td>
</tr>
<tr>
<td><strong>PaCO₂ (mmHg)</strong></td>
<td>65.1 (9.5)</td>
<td>--</td>
</tr>
<tr>
<td><strong>PaCO₂ (mmHg)</strong></td>
<td>39.8 (2.6)</td>
<td>--</td>
</tr>
<tr>
<td><strong>pH</strong></td>
<td>7.44 (0.20)</td>
<td>--</td>
</tr>
<tr>
<td><strong>SaO₂ (%)</strong></td>
<td>92.8 (2.2)</td>
<td>--</td>
</tr>
</tbody>
</table>

Values are mean (SD).

RESULTS

Baseline patient characteristics

Patients were characterised by severe airflow limitation, hypoxaemia without carbon dioxide retention at rest, reduced transfer factor and lung hyperinflation, as reflected by increased functional residual capacity (table 1). Age and BMI were not significantly different between patients with COPD and healthy controls (table 1).

Exercise training programme

Examination of the mean training intensity (interval = 115 (15)% and constant-load = 70 (5)% of baseline Wpeak) revealed that the total amount of work sustained during interval and constant-load training was comparable. Mean training intensity increased progressively throughout the rehabilitation programme such that, at weeks 3, 6 and 10, it corresponded to 100 (15)% and 130 (16)% of baseline Wpeak for interval training and to 62 (31), 70 (5)% and 81 (5)% of baseline Wpeak for constant-load training.

Exercise capacity

After rehabilitation there was a significant improvement in peak values of external work rate, oxygen uptake, lactate threshold and minute ventilation (table 2).

Skeletal muscle adaptations

The proportion of type I and type IIa fibres did not change significantly after training, whereas the proportion of type IIb fibres was significantly reduced (p < 0.05). The number of type IIb fibres was significantly reduced after training (table 3). Following

Table 2 Peak exercise responses before and after training in patients with COPD (n = 15)

<table>
<thead>
<tr>
<th></th>
<th>Before training</th>
<th>After training</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Work rate (W)</strong></td>
<td>50 (6)</td>
<td>55 (6)*</td>
</tr>
<tr>
<td><strong>VO₂ (mL/kg/min)</strong></td>
<td>12.1 (1.1)</td>
<td>13.3 (1.4)*</td>
</tr>
<tr>
<td><strong>LT (mL/kg/min)</strong></td>
<td>3.7 (0.6)</td>
<td>10.7 (2.4)*</td>
</tr>
<tr>
<td><strong>Ve (L/min)</strong></td>
<td>35.9 (3.2)</td>
<td>37.1 (3.1)*</td>
</tr>
<tr>
<td><strong>f_b (breaths/min)</strong></td>
<td>31 (2)</td>
<td>34 (2)*</td>
</tr>
<tr>
<td><strong>Vt (L)</strong></td>
<td>1.15 (0.08)</td>
<td>1.16 (0.09)</td>
</tr>
<tr>
<td><strong>SpO₂ (%)</strong></td>
<td>97 (9)</td>
<td>90 (1)</td>
</tr>
<tr>
<td><strong>RER</strong></td>
<td>0.98 (0.04)</td>
<td>0.99 (0.04)</td>
</tr>
<tr>
<td><strong>Dyspnoea (Borg)</strong></td>
<td>3.8 (0.4)</td>
<td>4.4 (0.4)</td>
</tr>
<tr>
<td><strong>Leg fatigue (Borg)</strong></td>
<td>3.9 (0.4)</td>
<td>3.6 (0.5)</td>
</tr>
</tbody>
</table>

Values are mean (SE).

Table 3 Effect of training on vastus lateralis characteristics in patients with COPD (n = 15)

<table>
<thead>
<tr>
<th></th>
<th>Before training</th>
<th>After training</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Fibre type distribution (%)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Type I</td>
<td>37 (4)</td>
<td>39 (4)</td>
</tr>
<tr>
<td>Type IIa</td>
<td>49 (4)</td>
<td>53 (5)</td>
</tr>
<tr>
<td>Type IIb</td>
<td>14 (3)</td>
<td>8 (1)*</td>
</tr>
<tr>
<td><strong>Cross-sectional area (μm²)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Type I</td>
<td>4606 (332)</td>
<td>5170 (372)*</td>
</tr>
<tr>
<td>Type IIa</td>
<td>4225 (295)</td>
<td>4711 (264)*</td>
</tr>
<tr>
<td>Type IIb</td>
<td>3236 (199)</td>
<td>3693 (209)*</td>
</tr>
</tbody>
</table>

Values are mean (SE).

*P<0.05 vs before training (paired t test).
rehabilitation the cross-sectional area of each fibre type was significantly increased (table 3), so the mean fibre cross-sectional area also increased significantly (from 4061 (254) \( \mu \text{m}^2 \) to 4581 (241) \( \mu \text{m}^2 \); p = 0.001).

**Plasma TNF\( \alpha \), IL-6 and CRP**

In patients with COPD the plasma concentrations of TNF\( \alpha \) (1.44 (0.17) pg/ml), IL-6 (5.68 (0.97) pg/ml) and CRP (0.97 (0.19) mg/dl) before training were significantly (p = 0.001) greater (by 3, 8 and 7-fold, respectively) than in healthy subjects (0.53 (0.12) pg/ml, 0.76 (0.17) pg/ml and 0.15 (0.04) mg/dl, respectively; fig 1). Following rehabilitation, the mean difference in TNF\( \alpha \) (−0.10 (95% CI −0.34 to 0.13) pg/ml), IL-6 (−0.59 (95% CI −2.8 to 1.7) pg/ml) and CRP (−0.15 (95% CI −0.7 to 0.6) mg/dl) in patients with COPD was not significant (fig 2).

**Skeletal muscle mRNA expression**

The mRNA contents were normalised for GAPDH\(^{24,27}\) and the results are given in relative units. Following exercise training, local muscle TNF\( \alpha \) mRNA expression was not significantly different from the level before training (1.24 (0.19) vs 1.37 (0.26), p = 0.73, fig 3A), corresponding to a mean difference from baseline of 10 (24)% (95% CI 49% to 66%), p = 0.74. In contrast, after training there was a significant increase in the expression of both IGF-I (by 72 (36)% (95% CI 12% to 155%), p = 0.046) and MyoD (by 67 (21)% (95% CI 18% to 116%), p = 0.012; fig 5).

**Skeletal muscle TNF\( \alpha \) protein**

To test whether the changes observed at the mRNA level were also extended to the protein level, muscle tissue was analysed by Western blotting. Representative Western blots are shown in fig 5. Based on densitometric analysis, it was determined that expression of TNF\( \alpha \) was not significantly changed after rehabilitation (9 (24)% (95% CI −49% to 66%), p = 0.74). In contrast, after training there was a significant increase in the expression of both IGF-I (by 72 (36)% (95% CI 12% to 155%), p = 0.046) and MyoD (by 67 (21)% (95% CI 18% to 116%), p = 0.012; fig 5).

**DISCUSSION**

Although the involvement of systemic inflammation in peripheral muscle dysfunction has never been directly documented in COPD, the available literature strongly supports a casual relationship.\(^{1-4}\) Regular exercise training is known to partially reverse the peripheral muscle abnormalities,\(^{12-13}\) but it is uncertain whether this is the result of reversing the effects of deconditioning alone or if muscle reconditioning actually decreases the peripheral muscle inflammation. The results of the present study show that lower limb exercise training...
induces significant adaptations in vastus lateralis fibre size and typology without reducing the systemic inflammatory mediator levels or the local muscle expression of TNFα and IL-6. As these skeletal muscle adaptations were accompanied by significant increase in factors regulating skeletal muscle hypertrophy and regeneration (ie, local muscle total IGF-I, MGF and MyoD expression), it is suggested that the peripheral muscles of patients with COPD retain adequate plasticity for remodelling in response to exercise training.

We investigated the effects of peripheral muscle training on specific systemic inflammatory mediator levels (TNFα, IL-6 and CRP) which have been proposed to be associated with muscle dysfunction in COPD. Compared with healthy age-matched controls, the patients exhibited significantly raised plasma levels of TNFα (3-fold), IL-6 (8-fold) and CRP (7-fold). The fold increase of these mediators before rehabilitation in our COPD patients relative to healthy controls are in line with those previously reported in patients with stable COPD of similar severity and body mass index. Although lack of change in systemic levels of TNFα and IL-6 with exercise training has previously been reported, to our knowledge this is the first study in patients with COPD to report a lack of effect of rehabilitation on systemic CRP levels. This is an interesting finding since CRP has been implicated as a marker for impairment in exercise capacity and respiratory distress.

With the present rehabilitation programme, local muscle TNFα mRNA and protein levels were not significantly changed, thus expanding the results of Rabinovich et al who found unchanged levels of muscle TNFα mRNA expression in patients on completion of a similar endurance training programme. In addition, the current study is the first to our knowledge to examine the effects of training on vastus lateralis muscle IL-6 mRNA expression in patients with COPD. The lack of change in local muscle IL-6 mRNA expression corroborates previous results in healthy individuals that exercise training does not effect local muscle IL-6 mRNA expression.

In the study by Rabinovich et al a lack of training-induced downregulation of muscle TNFα mRNA expression was attributed to the lower muscle antioxidant capacity in COPD compared with healthy controls. Furthermore, Mercken et al have shown that patients with COPD have higher levels of systemic and pulmonary oxidative stress markers after endurance exercise than age-matched healthy subjects and, although they tend to be reduced after pulmonary rehabilitation, they remain at higher levels than in healthy controls. Since muscle inflammation, tissue hypoxaemia and oxidative stress are strongly associated in COPD, it is possible that, with the present training programme, the repeated intense exercise sessions in chronically hypoxaemic patients may have exaggerated muscle oxidative stress, thus preventing a significant reduction in local muscle TNFα and IL-6 mRNA expression.

Animal studies have shown that local muscle TNFα and IL-6 expression impairs the ability of IGF-1 to promote protein synthesis and inhibits the expression of critical muscle-specific transcription factors such as MyoD, resulting in skeletal muscle atrophy. It is therefore interesting to note that the significant training-induced upregulation of both muscle IGF-I and MyoD mRNA expression and changes in fibre morphological characteristics occurred despite the finding that muscle TNFα and IL-6 mRNA expression was not significantly decreased after training. A possible explanation for these findings is that regular work overload is a powerful stimulus modulating an increase in factors that regulate myofibril hypertrophy, thereby exceeding the potentially negative impact
reduce the local muscle mRNA expression of IL-6. The chronic heart failure, exercise training has also been shown to quantified by densitometric analysis. Growth factor-I (IGF-I) and MyoD relative to α-actinin antibody. Data quantified by densitometric analysis.

Effects of rehabilitative exercise on peripheral muscle TNFα

Figure 5 Representative pre-and post-training Western blots for four patients for local muscle tumour necrosis factor α (TNFα), insulin-like growth factor-I (IGF-I) and MyoD relative to α-actinin antibody. Data quantified by densitometric analysis.

of TNFα and IL-6 on muscle architecture. On the other hand, exercise training in patients with chronic heart failure and healthy elderly subjects has been shown to decrease skeletal muscle TNFα mRNA expression and induce muscle fibre hypertrophy, thereby suggesting that training may reduce the inhibitory effect of TNFα on muscle protein synthesis. In chronic heart failure, exercise training has also been shown to reduce the local muscle mRNA expression of IL-6. The duration of the training programme for 6 months in patients with chronic heart failure and/or the mode of exercise (resistance) in healthy elderly individuals may account for the differences between those two studies and the current study with regard to the effects of training on muscle inflammation.

In tandem with our previous findings, rehabilitative training induced a significant improvement in the cross-sectional areas of all fibre types. Although it is known that the muscles of patients with COPD can hypertrophy in response to endurance training, the coupling to local growth factor expression has not previously been demonstrated. The present study is therefore the first to show that muscle fibre hypertrophy is accompanied by significant upregulation of IGF-I (both at mRNA and protein levels) that is known to play an important role in the hypertrophic adaptation of muscle to overloading. The magnitude of the increase in IGF-I mRNA expression (by ~70%) in our COPD population is similar to that reported in patients with chronic heart failure after endurance training (by ~80%), although it is lower than the increase reported after resistance training (by ~300–500%) in healthy elderly subjects.

Interestingly, the present study also showed a significant increase (by ~70%) in the expression of one of the three isoforms of IGF-I (ie, MGF) that is known to be sensitive to mechanical loading and to be upregulated after resistance training in healthy elderly individuals (increase in mRNA by ~160%). It is therefore suggested that the muscles of patients with COPD are able to upregulate MGF mRNA in response to a period of endurance training.

The expression of MyoD is known to be highly induced after resistance training in healthy elderly individuals but, to the best of our knowledge, an increase in MyoD expression has not previously been reported after an endurance training programme in humans. MyoD is expressed in muscle satellite cells and mature myofibres and has been implicated in mediating the process of cell proliferation and differentiation for subsequent muscle regeneration and hypertrophy. Accordingly, it can be hypothesised that the repeated bouts of muscle loading within the present training programme caused significant upregulation of MyoD mRNA expression due to the activation of satellite cells for muscle repair/regeneration. The increase in local muscle MyoD protein levels was of a smaller magnitude than the mRNA expression. It has been suggested that, owing to a number of post-transcriptional controls (eg, RNA splicing, RNA editing, blocked nuclear export, subcellular localisation, negative translational control), a close relationship between mRNA and protein would not be expected.

**Study limitations**

The invasive nature of the muscle biopsies precluded a parallel, aged-matched, healthy control training group which would allow comparisons in training-induced changes in local muscle inflammatory and growth factors between healthy subjects and patients with COPD. However, in the study of Rabinovich et al., where such a control group was available, exercise training did not significantly modify local muscle TNFα mRNA in healthy subjects. In addition, another study involving endurance exercise training in healthy elderly individuals confirmed that this type of training does not impact on local muscle TNFα protein levels. Moreover, IGF-I, MGF and MyoD mRNA levels have been shown to increase after resistance training in healthy subjects aged matched with those of our study.

Although our previous work established no differences between training strategies in terms of muscle morphological characteristics, it is possible that the effectiveness of one of the two training modalities might be superior in terms of local muscle expression of growth and myogenic regulatory factors. However, in the present study there was not sufficient power within the two modalities to look for such differences. Future studies including larger sample size within each training group will allow such a comparison.

In conclusion, the results of the present study show that, in the absence of a decrease in systemic or local muscle TNFα and IL-6, endurance exercise training in COPD induces peripheral muscle adaptations that are accompanied by upregulation of factors regulating skeletal muscle hypertrophy and regeneration.

Further information is given in the online supplement available at http://www.thoraxbmj.com/supplemental

---

**Authors’ affiliations**

Ioannis Vogiatzis, Gerasimos Terzis, National and Kapodistrian University of Athens, Department of Physical Education and Sport Science, Athens, Greece

Grigoris Stratakos, Davina C M Simoes, Olga Georgiadou, Charis Roussos, Spyros Zakynthinos, National and Kapodistrian University of Athens, Department of Critical Care Medicine and Pulmonary Services, Pulmonary Rehabilitation Centre, Evangelismos Hospital, G.P. Livanos and M. Simou Laboratories, Athens, Greece

This work was supported in part by the European Community CARED FP5 project (Contract No QLGS-CT-2002-0893), the Thorax Foundation and by Pfizer Inc (Contract No GA9000KS).

Competing interests: None.
REFERENCES